Accreditation/Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Merck & Co., Inc.

Community Practice Connections™: Leveraging Immunogenicity in Women's Cancers: The Experts Weigh in on Current Evidence and Practical Guidance in Cervical and Endometrial Cancers

Release Date: August 30, 2019
Expiration Date: August 30, 2020
Media: Internet - based

Activity Overview

Although cervical and endometrial cancers are associated with high rates of positive clinical outcomes when detected early enough, many cases are not detected until they have reached an advanced stage. The management of patients with advanced/metastatic disease remains an important clinical challenge. Pursuit of treatment options that may help to improve clinical efficacy and limit treatment-associated adverse events is an active area of investigation, with several options showing promise in recent studies. An understanding of the mechanisms underlying the development of these diseases has helped to inform new approaches to clinical management, which may improve outcomes for your patients. The optimal utilization of deficient mismatch repair/microsatellite instability assessment and other molecular testing may also improve the integration of new treatment options into clinical practice.

Keeping up with these advancements can be a challenging goal for busy clinicians, as can development of a thorough understanding of potential applications of new data from trials evaluating therapeutic approaches for advanced cervical and endometrial cancers. This interactive, online activity is designed to help clinicians achieve this. It is based on a live symposium held adjunct to the 2019 annual oncology meeting in Chicago. Through a series of brief video interviews, the multidisciplinary faculty—comprising renowned experts in gynecologic oncology and immunotherapy—review practice-changing data and their impact on patient care, discuss “real-world” clinical cases, and share forward-looking perspectives on the treatment horizon.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Merck & Co., Inc.

Instructions for This Activity and Receiving Credit

  • You will need to log in to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, “Educational Content/Video” will be available for your reference.
  • In order to receive a CME Certificate, you must complete the activity.
  • Complete the Posttest and pass with a score of 70% or higher, complete the Evaluation, and then click on “Request for Credit.” You may immediately download a CME Certificate upon completion of these steps.

Target Audience

This educational program is directed toward medical oncologists, pathologists, radiation oncologists, and surgical oncologists who treat and/or manage patients with endometrial and cervical cancers. Obstetrician/gynecologists, nurses, physician assistants, fellows, and residents with an interest in endometrial and cervical cancers are also invited to participate.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

  • Assess the current role of biomarkers to guide the potential application of immunotherapy for endometrial and cervical cancer.
  • Describe key safety and efficacy data regarding immunotherapies for patients with endometrial and cervical cancer.
  • Appraise current and emerging treatment combinations involving immunotherapy for women’s cancers.
  • Outline evidence-based approaches to mitigate adverse events associated with immunotherapy for patients with endometrial and cervical cancer.

Faculty, Staff, and Planners’ Disclosures

Faculty

Bradley J. Monk
Bradley J. Monk, MD, FACS, FACOG
Professor
Division of Gynecologic Oncology
Arizona Oncology (US Oncology Network) University of Arizona College of Medicine
Phoenix Creighton University School of Medicine at St. Joseph’s Hospital Medical Director
US Oncology Research Network ‒ Gynecologic Program
Phoenix, AZ

Disclosures: Consultant: AbbVie, Advaxis, Agenus, Amgen, AstraZeneca, ChemoCare, ChemoID, Clovis, Conjupro, Eisai, Geistlich, Genmab, ImmunoGen, Immunomedics, Incyte, Janssen/Johnson & Johnson, Mateon (formally OXiGENE), Merck, Myriad, NuCana, OncoMed, OncoQuest, OncoSec, Perthera, Pfizer, Precision Oncology, Puma, Roche/Genentech, Samumed, Takeda, Tesaro, VBL.

Deborah K. Armstrong
Deborah K. Armstrong, MD
Professor of Oncology
Professor of Gynecology and Obstetrics
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Baltimore, MD

Disclosures: Grant/Research Support: AstraZeneca, Clovis Oncology, Pfizer, Morphotek/Eisai, Tesaro, Syndax; Consultant: Cue Biopharma; Data Safety Monitoring Board: Member for AstraZeneca.

Robert L. Coleman
Robert L. Coleman, MD, FACOG, FACS
Professor and Executive Director, Cancer Network Research
Ann Rife Cox Chair in Gynecology
Department of Gynecologic Oncology and Reproductive Medicine The University of Texas MD Anderson Cancer Center
Houston, TX

Disclosures: Grant/Research Support: AstraZeneca, Clovis Oncology, Genentech/Roche, Janssen, Merck; Consultant: AbbVie, Cell Medica, COR2ED, Geistlich, Genmab, MoreHealth, Takeda, Tesaro; Speakers Bureau: Banner MDACC, Roche, Scripps MDACC; Scientific/Advisory Board: Aravive Biologics, ArQule, AstraZeneca, Clovis Oncology, Cordgenics, Eisai, Genentech, ImmunoGen, Merck, Mersana Therapeutics, Myriad Genetics, National Comprehensive Cancer Network, Novocure, OncoMed Pharmaceuticals, Tesaro.

Stéphanie Gaillard
Stéphanie Gaillard, MD, PhD
Director, Gynecologic Cancer Trials
Assistant Professor of Oncology
Assistant Professor of Gynecology & Obstetrics
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Baltimore, MD

Disclosures: Grant/Research Support: Pfizer, Genentech/Roche, Iovance Biotherapeutics, Merck, AbbVie, AstraZeneca; Consultant: AstraZeneca, ImmunoGen.

The staff of Physicians' Education Resource®, LLC (PER®), have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines relevant financial relationships as financial relationships in any amount occurring within the past 12 months that create a conflict of interest (COI).

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members, and do not reflect those of PER® or the company that provided commercial support for this program.


Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
1234567
891011121314
15161718192021
22232425262728
2930
Filter By